腹腔热灌注化疗对复发性卵巢癌预后影响的Meta分析
|
摘要
目的评估腹腔热灌注化疗(HIPEC)对复发性卵巢癌(ROC)预后的影响。方法计算机检索PubMed、Embase、Cochrane Library、Web of Science、中国知网、维普和万方等数据库,收集关于HIPEC治疗ROC的研究,对纳入研究进行质量评价。以风险比(HR)和95%可信区间(95%CI)为效应指标,采用Stata 12. 0软件进行Meta分析。结果共纳入6项研究,共计405例患者。Meta分析结果显示,HIPEC可以改善ROC患者的总生存期(P <0. 05,HR=0. 48,95%CI:0. 32,0. 71)。结论 HIPEC可以改善ROC患者的预后。
Objective To evaluate the effect of hyperthermic intraperitoneal chemotherapy( HIPEC) on the prognosis of patients with recurrent ovarian cancer( ROC). Methods A computer-based retrieval was performed in databases,such as PubMed,Embase,Cochrane Library,Web of Science,CNKI,VIP,WanFang Data and so on,to collect the trials on HIPEC for treating ROC,quality assessment of the included trials was carried out. Using hazard ratio( HR) and 95% confidence interval( 95% CI) as effect indicators,Stata 12. 0 software was adopted to conduct Meta-analysis. Results A total of 6 trials involving 405 patients were included. The results of Meta-analysis showed that HIPEC could improve the overall survival of patients with ROC( P < 0. 05; HR = 0. 48; 95% CI,0. 32-0. 71).Conclusion HIPEC can improve the prognosis of patients with ROC.
Objective To evaluate the effect of hyperthermic intraperitoneal chemotherapy( HIPEC) on the prognosis of patients with recurrent ovarian cancer( ROC). Methods A computer-based retrieval was performed in databases,such as PubMed,Embase,Cochrane Library,Web of Science,CNKI,VIP,WanFang Data and so on,to collect the trials on HIPEC for treating ROC,quality assessment of the included trials was carried out. Using hazard ratio( HR) and 95% confidence interval( 95% CI) as effect indicators,Stata 12. 0 software was adopted to conduct Meta-analysis. Results A total of 6 trials involving 405 patients were included. The results of Meta-analysis showed that HIPEC could improve the overall survival of patients with ROC( P < 0. 05; HR = 0. 48; 95% CI,0. 32-0. 71).Conclusion HIPEC can improve the prognosis of patients with ROC.
引文
[1] Siegel R,Ma JM,Zou Z,et al. Cancer statistics,2014[J].CA Cancer J Clin,2014,64(1):9-29.
[2] du Bois A,Reuss A,Pujade-Lauraine E,et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer:a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials:by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom(AGO-OVAR)and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire(GINECO)[J]. Cancer,2009,115(6):1 234-1 244.
[3] Zivanovic O,Abramian A,Kullmann M,et al. HIPEC ROC I:a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer[J]. Int J Cancer,2015,136(3):699-708.
[4] Sticca RP,Dach BW. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents[J]. Surg Oncol Clin N Am,2003,12(3):689-701.
[5] van Driel WJ,Koole SN,Sonke GS,et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer[J]. N Engl J Med,2018,378(14):1 363-1 364.
[6] Stirrups R. HIPEC improves survival in stageⅢepithelial ovarian cancer[J]. Lancet Oncol,2018,19(3):e138.
[7] Tierney JF,Stewart LA,Ghersi D,et al. Practical methods for incorporating summary time-to-event data into meta-analysis[J].Trials,2007,8:16.
[8] Wang Y,Zeng T. Response to:practical methods for incorporating summary time-to-event data into meta-analysis[J].Trials,2013,14:391.
[9] Spiliotis J,Halkia E,Lianos E,et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer:a prospective randomized phaseⅢstudy[J]. Ann Surg Oncol,2015,22(5):1 570-1 575.
[10] Safra T,Grisaru D,Inbar M,et al. Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression-free survival,especially in BRCA-positive patients-a case-control study[J]. J Surg Oncol,2014,110(6):661-665.
[11] Le Brun JF,Campion L,Berton-Rigaud D,et al. Survival benefit of hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer:a multi-institutional case control study[J]. Ann Surg Oncol,2014,21(11):3 621-3 627.
[12]王根和,方平,陈雍,等.口服足叶乙甙联合卡铂腹腔热灌注治疗多线化疗后复发性卵巢癌的临床研究[J].肿瘤药学,2014,4(4):272-276.
[13] Muoz-Casares FC,Rufián S,Rubio MJ,et al. The role of hyperthermic intraoperative intraperitoneal chemotherapy(HIPEC)in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer[J]. Clin Transl Oncol,2009,11(11):753-759.
[14]孙建华,姬忠贺,李雁.细胞减灭术加腹腔热灌注化疗治疗复发性卵巢癌[J].肿瘤学杂志,2018,24(3):240-246.
[15] Hanker LC,Loibl S,Burchardi N,et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy[J].Ann Oncol,2012,23(10):2 605-2 612.
[16] Marchetti C,De Felice F,Palaia I,et al. Efficacy and toxicity of bevacizumab in recurrent ovarian disease:an update meta-analysis on phaseⅢtrials[J]. Oncotarget,2016,7(11):13 221-13 227.
[17] Jiang G,Balboni T,Taylor A,et al. Palliative radiation therapy for recurrent ovarian cancer:efficacy and predictors of clinical response[J]. Int J Gynecol Cancer,2018,28(1):43-50.
[18] Bristow RE,Puri I,Chi DS. Cytoreductive surgery for recurrent ovarian cancer:a meta-analysis[J]. Gynecol Oncol,2009,112(1):265-274.
[19] Amate P,Huchon C,Dessapt AL,et al. Ovarian cancer:sites of recurrence[J]. Int J Gynecol Cancer,2013,23(9):1 590-1 596.
[20] Muller M,Chérel M,DupréPF,et al. Cytotoxic effect of hyperthermia and chemotherapy with platinum salt on ovarian cancer cells:results of an in vitro study[J]. Eur Surg Res,2011,46(3):139-147.
[2] du Bois A,Reuss A,Pujade-Lauraine E,et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer:a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials:by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom(AGO-OVAR)and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire(GINECO)[J]. Cancer,2009,115(6):1 234-1 244.
[3] Zivanovic O,Abramian A,Kullmann M,et al. HIPEC ROC I:a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer[J]. Int J Cancer,2015,136(3):699-708.
[4] Sticca RP,Dach BW. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents[J]. Surg Oncol Clin N Am,2003,12(3):689-701.
[5] van Driel WJ,Koole SN,Sonke GS,et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer[J]. N Engl J Med,2018,378(14):1 363-1 364.
[6] Stirrups R. HIPEC improves survival in stageⅢepithelial ovarian cancer[J]. Lancet Oncol,2018,19(3):e138.
[7] Tierney JF,Stewart LA,Ghersi D,et al. Practical methods for incorporating summary time-to-event data into meta-analysis[J].Trials,2007,8:16.
[8] Wang Y,Zeng T. Response to:practical methods for incorporating summary time-to-event data into meta-analysis[J].Trials,2013,14:391.
[9] Spiliotis J,Halkia E,Lianos E,et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer:a prospective randomized phaseⅢstudy[J]. Ann Surg Oncol,2015,22(5):1 570-1 575.
[10] Safra T,Grisaru D,Inbar M,et al. Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression-free survival,especially in BRCA-positive patients-a case-control study[J]. J Surg Oncol,2014,110(6):661-665.
[11] Le Brun JF,Campion L,Berton-Rigaud D,et al. Survival benefit of hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer:a multi-institutional case control study[J]. Ann Surg Oncol,2014,21(11):3 621-3 627.
[12]王根和,方平,陈雍,等.口服足叶乙甙联合卡铂腹腔热灌注治疗多线化疗后复发性卵巢癌的临床研究[J].肿瘤药学,2014,4(4):272-276.
[13] Muoz-Casares FC,Rufián S,Rubio MJ,et al. The role of hyperthermic intraoperative intraperitoneal chemotherapy(HIPEC)in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer[J]. Clin Transl Oncol,2009,11(11):753-759.
[14]孙建华,姬忠贺,李雁.细胞减灭术加腹腔热灌注化疗治疗复发性卵巢癌[J].肿瘤学杂志,2018,24(3):240-246.
[15] Hanker LC,Loibl S,Burchardi N,et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy[J].Ann Oncol,2012,23(10):2 605-2 612.
[16] Marchetti C,De Felice F,Palaia I,et al. Efficacy and toxicity of bevacizumab in recurrent ovarian disease:an update meta-analysis on phaseⅢtrials[J]. Oncotarget,2016,7(11):13 221-13 227.
[17] Jiang G,Balboni T,Taylor A,et al. Palliative radiation therapy for recurrent ovarian cancer:efficacy and predictors of clinical response[J]. Int J Gynecol Cancer,2018,28(1):43-50.
[18] Bristow RE,Puri I,Chi DS. Cytoreductive surgery for recurrent ovarian cancer:a meta-analysis[J]. Gynecol Oncol,2009,112(1):265-274.
[19] Amate P,Huchon C,Dessapt AL,et al. Ovarian cancer:sites of recurrence[J]. Int J Gynecol Cancer,2013,23(9):1 590-1 596.
[20] Muller M,Chérel M,DupréPF,et al. Cytotoxic effect of hyperthermia and chemotherapy with platinum salt on ovarian cancer cells:results of an in vitro study[J]. Eur Surg Res,2011,46(3):139-147.